



Press Release
July 11, 2012



Strides Arcolab Limited,
Strides House,
Bannerghatta Road,
Bangalore – 560076, India

BSE: 532531
NSE: STAR

AGILA ANNOUNCES ENTRY INTO CANADIAN INJECTABLE MARKET

- **Sets up Sales and Marketing JV with Jamp Pharma**
 - **Agila-Jamp to offer wide selection of generic injectable drugs**
 - **New Source of Generic Injectable Drugs to ease supply issue in Canada**
-


Bangalore, July 11, 2012; Agila Specialties Pharma Corporation, Canada, which is part of the injectable drug division of Strides Arcolab, a globally renowned generic drug manufacturer, has formed a joint venture with Jamp Pharma, a Canadian generic drug company, to introduce a variety of quality injectable generic drugs in Canada.

This sales and marketing joint venture will operate under the name 'Agila-Jamp Canada Inc' in which Agila will hold 70% stake and the remaining 30% by Jamp Pharma. The JV will be headquartered in Boucherville, Québec.

Agila-Jamp will be launching around 40 products in the next 2 years. Many of these products have already been approved by Health Canada and will be immediately launched through local hospitals and pharmacists. The existing sales force at Jamp Pharma will be responsible to introduce the entire Agila-Jamp product portfolio.

"We have been looking to bring our quality products to Canada for quite some time. We have found in Jamp Pharma, a company that understands and will help us develop a market which needs our expertise in the development and manufacturing of injectable drugs," declared Adam Levitt, CEO- North America.

"Recent events have demonstrated that Canada is in dire need for a more diversified offering in terms of quality injectable generic drugs. Canadian hospitals, pharmacists and patients must be able to rely on a regular, steady and safe supply of critical and essential injectable drugs. We are proud that our products will help our healthcare system," said Mr. Louis Pilon, President and CEO Jamp Pharma.



About Agila Specialties

Agila, Specialties business of Strides Arcolab is focused on key domains such as oncolytics, penems, pencillins, cephalosporins, ophthalmics, peptides and biosimilars and operates from 9 world-class global manufacturing facilities, including one of the largest steriles capacity in India and amongst the largest lyophilization (freeze drying) capacities in the world. Agila's marketing network covers 70 countries and it has partnerships with some of the world's leading pharmaceutical companies for both developed and emerging markets.

About Strides Arcolab

Strides Arcolab, listed on the Bombay Stock Exchange Limited (532531) and National Stock Exchange of India Limited (STAR), is a global pharmaceutical company headquartered in Bangalore, India that develops and manufactures a wide range of IP-led niche pharmaceutical products with an emphasis on sterile injectables.

The company has 14 manufacturing facilities across 6 countries with presence in more than 75 countries in developed and emerging markets. Manufacturing is ably supported by a 350-scientist strong global R&D Centre located in Bangalore.

Additional information is available at the company's website at www.stridesarco.com.

About JampPharma

Founded in 1988, JampPharma Corporation is a private-held Canadian company. The company specializes in the development, the distribution and marketing of branded generic drugs and non-prescription products. For the last several years, JAMP has been experiencing solid growth.

Mr. Louis Pilon has been the President and CEO of Jamp since March 2006. Jamp's head office and distribution center is located in Boucherville, Quebec

About Strides Arcolab Limited

For further information, please contact:

<u>Strides</u> Mr. Ajay Singh : +91 80 6784 0813 Mr. Kannan N : +91 98450 54745	<u>PR Consultancy</u> Corporate Voice Weber Shandwick Mahesh Nair, +91 9880376648 maheshn@corvoshandwick.co.in Kaveri Mandanna, +91 90089 59697 kaveri@corvoshandwick.co.in
--	--

